Activity Summary:
Despite dramatic advances in the development of treatments for pulmonary arterial hypertension (PAH), it remains a chronic life-threatening illness for which there is no cure. Advances in knowledge within the field are eagerly anticipated.

These educational podcasts will spotlight important research into the basic science, diagnosis, treatment, and medical management of patients with PAH based on data presented at the American College of Chest Physicians (CHEST) Annual Meeting in Boston, MA October 6-9, 2024.

Activity Summary:
Despite dramatic advances in the development of treatments for pulmonary arterial hypertension (PAH), it remains a chronic life-threatening illness for which there is no cure. Advances in knowledge within the field are eagerly anticipated.

These educational Clinical Clips will spotlight important research into the basic science, diagnosis, treatment, and medical management of patients with PAH based on data presented at the American College of Chest Physicians (CHEST) Annual Meeting in Boston, MA October 6-9, 2024.

Activity Summary:
Recent data suggests that PAH is now frequently diagnosed in older patients who often present with cardiovascular (CV) comorbidities. Many patients present with CV comorbidities that are uncontrolled, creating a management dilemma for the treating physician. This slide set presents two case studies discussing the clinical approach as well as how to control comorbidities and their impact on the pulmonary circulation with the best treatment approach for this population.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Heart failure (HF) is a complex syndrome and a growing problem, in terms of both the number of patients affected, its associated clinical consequences and its implications for health care expenditure. HF is recognized as the ultimate pathway of cardiovascular disease (CVD). Importantly, rapid ageing of the population means that the incidence of HF shall increase further in the coming years. Preventing the development of this condition in the population at large, in order to reduce hospital readmission rates, its other clinical sequelae and its economic consequences, is a key issue in modern medicine. Appropriate HF treatment can have the greatest influence on prolonging patients' lives in the coming year. Typically, HF is a common and insidious disease with substantial associated morbidity and mortality burden worldwide. This has led to a significant focus on improving treatments and medical therapy for this condition.

This podcast will provide expert interpretation of recent clinical trial evidence for CV risk reduction in people with HF, examining results of new therapeutic approaches for the treatment of HF presented at the 73rd Annual Scientific Session & Expo of American College of Cardiology (ACC 2024), April 6-8, Atlanta, GA.

Activity Summary:
Heart failure (HF) is a complex syndrome and a growing problem, in terms of both the number of patients affected, its associated clinical consequences and its implications for health care expenditure. HF is recognized as the ultimate pathway of cardiovascular disease (CVD). Importantly, rapid ageing of the population means that the incidence of HF shall increase further in the coming years. Preventing the development of this condition in the population at large, in order to reduce hospital readmission rates, its other clinical sequelae and its economic consequences, is a key issue in modern medicine. Appropriate HF treatment can have the greatest influence on prolonging patients' lives in the coming year. Typically, HF is a common and insidious disease with substantial associated morbidity and mortality burden worldwide. This has led to a significant focus on improving treatments and medical therapy for this condition.

This clinical clip will provide expert interpretation of recent clinical trial evidence for CV risk reduction in people with HF, examining results of new therapeutic approaches for the treatment of HF presented at the 73rd Annual Scientific Session & Expo of American College of Cardiology (ACC 2024), April 6-8, Atlanta, GA.

Activity Summary:
Dyslipidemia is a well-known risk factor for the development of cardiovascular disease, a leading cause of morbidity and mortality. Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this podcast series, Dr. Deepak Bhatt and Dr. R. Scott Wright discuss recent clinical trial evidence for CV risk reduction with cholesterol-lowering therapies, with a focus on CV outcomes trials with current and emerging therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9).

Activity Summary:
Dyslipidemia is a well-known risk factor for the development of cardiovascular disease, a leading cause of morbidity and mortality. Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this webcast archive, Dr. Deepak Bhatt and Dr. R. Scott Wright discuss recent clinical trial evidence for CV risk reduction with cholesterol-lowering therapies, with a focus on CV outcomes trials with current and emerging therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9).

Activity Summary:
This AMA/ANCC/ACPE activity features a recorded discussion among three leading pulmonary hypertension (PH) experts and is designed to keep healthcare professionals on top of the most recent clinical findings.

This activity provides an expert discussion around the updated guidelines from the European Society of Cardiology (ESC) and European Respiratory Society (ERS) as well as research presented at both ERS and CHEST 2022. These discussions provide the latest evidence for the care of patients with pulmonary hypertension based on data released from these conferences. Additionally, this activity also discusses the array of registry databases, what information has been yielded about the demographic factors, treatment, and survival of patients, as well as their limitations, which provides real-world evidence that informs clinical practice and health policy.

Activity Summary:
Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee.

Pulmonary arterial hypertension (PAH) is a progressive and fatal lung disease of multifactorial etiology. Currently, therapies for treating pulmonary hypertension have been used alone and in combination to demonstrate improvements in quality of life and hemodynamic parameters as well as in slowing disease progression; however, beneficial effects on survival are limited. None offer a cure against PAH nor directly address the underlying cellular proliferation that leads to increased pulmonary arterial pressure, and the median survival rate remains at 61% at five years after diagnosis. Extensive research efforts have led to the emergence of innovative therapeutic approaches in PAH. This on-demand webcast focuses on several important aspects of PAH management, including a discussion of the challenges diagnosing and treating patients, clinical trial data on emerging therapeutics for the management of PAH, and a review of strategies to optimize outcomes for patients with PAH.

Activity Summary:
Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee.

Recent progress in pulmonary arterial hypertension (PAH) is based on new strategies for combination therapy and the escalation of treatments to improve the significant morbidity and mortality associated with this disease. This on-demand presentation is a case-based discussion on the importance of a proper workup to reach the correct diagnosis and monitoring patients to determine when and how to optimally alter their PAH therapy.

Activity Summary:
This AMA/ANCC/ACPE activity features a recorded discussion among three leading pulmonary hypertension (PH) experts and is designed to keep healthcare professionals on top of the most recent clinical findings.

New information is constantly being learned about the management of patients with PH. Pulmonary Hypertension Due to Interstitial Lung Disease (PH-ILD) represents a complex condition which now has a recently approved inhaled therapy to improve exercise ability. Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but treatable complication of PE, which is often indistinguishable from pulmonary arterial hypertension (PAH). All patients with PH benefit from intensive, continuous clinical monitoring either in person or remotely to guide escalation of treatments. PH remains a disease with poor outcomes, necessitating early diagnosis and appropriate intervention. Improvements in survival and care depends on improving clinician awareness of the latest research and perspectives. This activity brings cutting-edge research to busy clinicians enabling them to readily keep abreast of emerging published research as it relates to the management of PH.

Activity Summary:
Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee.

Through patient cases, Sonja Bartolome, MD, FCCP and Dunbar Ivy, MD provide learners with the opportunity to enhance clinical decision-making skills about the diagnosis and management of PAH. This on-demand presentation will take the learner through a complete virtual patient tour starting at the time of symptoms of PAH through diagnosis, evaluation, and how the disorder is managed. In Case 1, Dr. Bartolome presents how to manage the complications and precautions in a patient through pregnancy, labor and delivery, and the immediate postpartum period. In Case 2, Dr. Ivy presents the common features of pediatric PAH with adult disease including the challenges that require unique approaches.

Activity Summary:
Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee.

Through patient cases, Usha Krishnan, MD, DM, FAHA and Nicholas Hill, MD discuss the key considerations to manage patients with pulmonary arterial hypertension (PAH). In Case 1, Dr. Krishnan presents the patient with underlying cardiac defects and repair history and lifelong management in multidisciplinary specialty centers with expertise in pulmonary arterial hypertension - congenital heart disease (PAH-CHD). In Case 2, Dr. Hill discusses how to manage the patient with acute right ventricle (RV) failure.

Activity Summary:
This accredited AMA/ANCC/ACPE activity features a recorded discussion among three experts and is designed to keep healthcare professionals on top of the most recent clinical findings in PAH.

The fourth edition will feature Dr. Dunbar Ivy, Dr. Marc Humbert and Dr. Ronald Oudiz discussing an Update on Pediatric PAH Care; Patient Perspectives in PAH and What’s New in Imaging in PAH​.

Activity Summary:
This accredited continuing education activity features a recorded discussion among three experts and is designed to keep healthcare professionals abreast of the most recent clinical findings in pulmonary arterial hypertension (PAH).

In this edition, Dr. Ronald Oudiz, Dr. Aaron Waxman and Dr. Marius Hoeper discuss past and future challenges of the World Symposium on Pulmonary Hypertension (WSPH), cardiopulmonary exercise testing in PH and the unmet clinical needs in systemic sclerosis-associated PAH (SSc-PAH).

Activity Summary:
This AMA/ANCC/ACPE activity features a recorded discussion among three experts and is designed to keep healthcare professionals abreast the most recent clinical findings in PAH.

The second edition will feature Dr. Ronald Oudiz, Dr. Nicholas Hill and Dr. Richard Channick discussing congress highlights from the International Society for Heart and Lung Transplantation and American Thoracic Society 2021, intensive care management of the PAH patient with COVID-19 and recent updates to the medical management of patients with CTEPH.

Activity Summary:
This AMA/ANCC/ACPE activity features a recorded discussion among three experts and is designed to keep healthcare professionals on top of the most recent clinical findings in PAH.

The first edition will feature Dr. Ronald Oudiz, Dr. Murali Chakinala and Dr. Harrison Farber discussing updates on COVID-19 & PAH and recent treatment strategies of PAH and emerging research for 2021.

Activity Summary:
Conversations in PAH are accredited, on-demand video presentations that feature PAH experts discussing hot topics, recent clinical updates, conference updates and treatment options for managing patients with PAH. This activity is designed to keep healthcare professionals on top of the most recent clinical findings in PAH. A new video series will be released every quarter throughout 2021.

Activity Summary:
In the past decade, it has become increasingly clear that women and men with stable ischemic heart disease often present with different signs and symptoms. Some of these differences can reflect gender-based differences in disease pathophysiology and risks for clinical cardiovascular events, as well as the need for different diagnostic methods and treatment strategies.

These educational Mini Modules will outline the epidemiologic trends as well as the health and economic burden of SIHD in women. In addition, discussion will include gender-specific pathophysiologic factors in SIHD, diagnostic approaches, risk stratification, and management approaches in women with stable ischemic heart disease.

Activity Summary:
Reducing the risk of death and major cardiovascular events are major goals of therapy for people with stable ischemic heart disease. Many management decisions hinge on a patient’s risk for these events, and recent and ongoing trials are helping to clarify treatment decisions in patients in different risk categories.

These educational Mini Modules will outline the role of medical therapies and revascularization when the goal of therapy is to reduce cardiovascular events and improve survival.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Major goals of therapy for people with stable ischemic heart disease (SIHD) include reducing angina symptoms and improving functional ability and quality of life. Recent developments in the use of medical therapies and re-evaluations of older therapies have brought some important changes to the treatment of these patients. Application of the results of revascularization trials and current recommendations requires careful and skillful risk stratification as well as a thorough understanding of the trial designs and results.

These educational Mini Modules will outline how recent developments and clinical trials influence the management of symptoms and functional limitations in real-world patients with stable ischemic heart disease.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Diabetes is a strong risk factor for cardiovascular disease, and it influences management and outcomes of existing disease.

These educational Mini Modules will outline how diabetes influences the onset and management of stable ischemic heart disease (SIHD), including choices of medical therapies and decisions about the use of revascularization strategies.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.